Skip to main content

Table 1 Characteristics of patients with chronic HCV infection

From: Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

Variables

PEG-IFN alfa-2a

PEG-IFN alfa-2b

P*

 

(n=402, 60.8%)

(n=259, 39.2%)

 

Genotype 1 (n=416), n (%)

254 (61.1)

162 (38.9)

 

Age, years

49 ± 11

51 ± 11

0.26

 >50 years, n (%)

121 (47.6)

83 (51.2)

0.48

Gender (male), n (%)

154 (60.6)

100 (61.7)

0.74

Weight (Kg)

67 ± 12

66 ± 11

0.93

 ≥ 75 kg, n (%)

48 (18.9)

34 (21.0)

0.62

BMI (Kg/m2)

24.3 ± 3.2

24.4 ± 3.1

0.81

WBC (/mm3)

5.5 ± 2.1

5.2 ± 1.6

0.11

Hemoglobin (g/dL)

13.9 ± 1.8

13.9 ± 1.7

0.72

Platelet (x103/mm3)

173 ± 72

167 ± 71

0.46

ALT (IU/L)

104 ± 86

94 ± 80

0.26

HCV RNA (IU/mL)

2.9×106 ± 1.1×106

4.8×106 ± 1.9×106

0.24

Fibrosis (stage), F0-2/F3-4, n (%)§

62/43 (59.0/41.0)

18/6 (75.0/25.0)

0.17

Adherence, ≥ 80%/<80%

171/83 (67.3/32.7)

115/47(71.0/29.0)

0.45

Genotype 2 or 3 (n=235), n (%)

141 (60.0)

94 (40.0)

 

Age, years

49 ± 12

51 ± 11

0.19

 >50 years, n (%)

61 (43.3)

49 (52.1)

0.19

Gender (male), n (%)

79 (56.0)

54 (57.4)

0.89

Weight (Kg)

65 ± 11

64 ± 10

0.51

 ≥ 75 kg, n (%)

25 (17.7)

11 (11.7)

0.27

BMI (Kg/m2)

23.8 ± 3.3

23.9 ± 2.7

0.98

WBC (/mm3)

5.3 ± 1.5

5.1 ± 1.8

0.46

Hemoglobin (g/dL)

14.2 ± 1.6

13.7 ± 1.5

0.06

Platelet (x103/mm3)

177 ± 62

168 ± 65

0.32

ALT (IU/L)

98 ± 88

90 ± 89

0.51

HCV RNA (IU/mL)

2.0×106 ± 1.9×106

1.9×106 ± 1.0×106

0.83

Fibrosis (stage), F0-2/F3-4, n (%)#

51/10 (83.6/16.4)

8/5 (61.5/38.5)

0.12

Adherence, ≥ 80%/<80%

107/34 (75.9/24.1)

78/16 (83.0/17.0)

0.26

Genotype others (n=10), n (%)

7(70.0)

3 (30.0)

 
  1. Abbreviation: HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; PEG-IFN, peginterferon; F0-2, no or insignificant fibrosis; F3-4, significant fibrosis or cirrhosis.
  2. mean ± standard deviation.
  3. §, # Data were available only in 129 (genotype 1) and 74 (genotype 2/3) patients who underwent liver biopsy before initiation of antiviral treatment.